Barclays PLC Raises Stake in Cerus Co. (NASDAQ:CERS)

Barclays PLC lifted its position in Cerus Co. (NASDAQ:CERS) by 16.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,575,049 shares of the biotechnology company’s stock after purchasing an additional 219,755 shares during the period. Barclays PLC owned about 0.85% of Cerus worth $2,740,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. XTX Topco Ltd boosted its holdings in Cerus by 18.7% in the 3rd quarter. XTX Topco Ltd now owns 178,431 shares of the biotechnology company’s stock worth $310,000 after buying an additional 28,063 shares during the period. State Street Corp lifted its position in shares of Cerus by 2.2% in the third quarter. State Street Corp now owns 3,738,893 shares of the biotechnology company’s stock valued at $6,506,000 after acquiring an additional 79,505 shares in the last quarter. Stifel Financial Corp boosted its stake in shares of Cerus by 12.0% in the third quarter. Stifel Financial Corp now owns 264,672 shares of the biotechnology company’s stock worth $461,000 after acquiring an additional 28,383 shares during the period. FMR LLC grew its position in shares of Cerus by 23.7% during the third quarter. FMR LLC now owns 541,220 shares of the biotechnology company’s stock worth $942,000 after purchasing an additional 103,596 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd raised its stake in Cerus by 1,182.9% during the 3rd quarter. Dynamic Technology Lab Private Ltd now owns 132,628 shares of the biotechnology company’s stock valued at $231,000 after purchasing an additional 122,290 shares during the period. 78.37% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, Director Eric Bjerkholt sold 20,000 shares of the firm’s stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $1.78, for a total value of $35,600.00. Following the completion of the transaction, the director now directly owns 162,133 shares of the company’s stock, valued at approximately $288,596.74. This trade represents a 10.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 3.40% of the company’s stock.

Analysts Set New Price Targets

Separately, Stifel Nicolaus dropped their price target on Cerus from $6.00 to $3.00 and set a “buy” rating for the company in a research note on Thursday, October 17th.

Cerus Stock Performance

Shares of Cerus stock opened at $1.58 on Wednesday. The company has a quick ratio of 1.92, a current ratio of 2.59 and a debt-to-equity ratio of 1.19. The firm has a market cap of $293.43 million, a price-to-earnings ratio of -14.36 and a beta of 1.24. Cerus Co. has a twelve month low of $1.38 and a twelve month high of $2.59. The business has a 50-day moving average price of $1.73 and a 200-day moving average price of $1.90.

Cerus Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.